# DEPARTMENT OF HEALTH

Evaluation of Multiplexing Spinal Muscular Atrophy with a Laboratory Developed Severe Combined Immunodeficiency Assay in Minnesota

Carrie Wolf, MBS | Laboratory Supervisor

- Minnesota has been screening for SCID since January 2013
- A SMA assay was developed by the CDC's Newborn Screening and Molecular Biology Branch and transferred to the Minnesota Newborn Screening Laboratory
- Minimal changes to the current SCID assay are needed to include SMA screening

 Comparison between current SCID assay (TREC & RNaseP) and a multiplexed SCID/SMA assay (TREC/RNaseP/SMN 1).

• Analysis of 4 SCID/SMA assays

Comparison of 2 DNA extractions for each assay

### **Old Versus New**

# SCID Assay

# SCID/SMA Assay



# Unaffected Versus Affected SMA Patient

# SMA Negative

# **SMA** Positive



# 4 SCID/SMA Assay Comparison

Assay A	Assay B	Assay C	Assay D
TREC/RNaseP Reagents	TREC/RNaseP Reagents	TREC/RNaseP Reagents	TREC/RNaseP Reagents
SMN Exon Forward	SMN Exon Forward	SMN Exon Forward	PE Forward
SMN Exon Reverse	SMN1 Exon-Intron <b>LNA</b> Reverse	SMN Exon Reverse	PE Reverse
SMN 1 Exon <b>RS</b> Probe	SMN1 Exon <b>RS</b> Probe	SMN1 Exon <b>FS</b> Probe	PE Probe
Annealing Temp. 65 <sup>0</sup> C	Annealing Temp. 65 <sup>0</sup> C	Annealing Temp. 63 <sup>0</sup> C	Annealing Temp. 60 <sup>0</sup> C

# Control Results

	Assay A	Assay B	Assay C	Assay D
	Avg Cq	Avg Cq	Avg Cq	Avg Cq
SMA Normal	23.55	24.50	25.65	22.87
SMA Positive 1	30.16	38.19	No Amplification	No Amplification
SMA Positive 2	30.53	38.48	No Amplification	No Amplification
SMA Positive 3	34.06	36.43	No Amplification	No Amplification
Carrier	22.60	23.36	23.51	21.30

# **DNA Extractions**



# **QIAGEN** Extraction

#### QIAGEN Extraction Median Cq



Assay A Assay B Assay C Assay D

#### Ē

# **Extracta DBS Extraction**

#### Extracta DBS Extraction Median Cq



- SMA can be added to the current SCID assay with minimal changes
- All assay conditions (A,B,C and D) give very comparable results
- The assay will NOT detect carriers
- No additional laboratory analysts will be needed to run the assay
- By multiplexing the assay, the cost will be increased by a little as \$0.15 per reaction

# Next Steps

- A validation of the SCID/SMA assay is in process
- SMA as a candidate condition is currently under review by the Minnesota Advisory Committee on Heritable and Congenital Disorders for recommendation of the addition of the disorder.
- Minnesota Department of Health will be activating a SMA workgroup comprised of specialists, pediatricians, and community advocates this Fall.

# Acknowledgments

### **The Centers for Disease Control and Prevention**

- Francis Lee
- **Kristina Mercer**

### **PerkinElmer**

- Kent Moore
- Janet Albrecht

### **Minnesota Department of Health**

- Berta Warman
- Trenna Lapacinski
- Kristen Bye



Carrie Wolf, MBS carrie.wolf@state.mn.us 651-201-5458

# Thank you!